Quest Diagnostics to Provide Diagnostic Testing Services for the Women of Ireland through Ireland's First Nationwide Cervical-Cancer Screeni...( MADISON N.J. June 20 /- Women in ...),Health

MADISON, N.J., June 20 /PRNewswire-FirstCall/ -- Women in Ireland will soon be able to take advantage of diagnostic testing services provided by Quest Diagnostics Incorporated (NYSE: DGX), the world's leader in cervical-cancer screening services. Through a contract with the Irish National Cancer Screening Service (NCSS), Quest Diagnostics will provide quality-assured screening services intended to improve medical outcomes and reduce anxiety wait time for women ages 25 to 60 who participate in Ireland's first nationwide cytology-screening program.

"Cervical cancer is a terrible disease that often strikes when a woman is in the prime of her life," said Ronald Kennedy, M.D., Corporate Medical Director, Quality Assurance in Anatomic Pathology, Quest Diagnostics. "Our goal for this historic cytology-screening program is to ensure that Irish women experience the highest quality of testing and service excellence, with the goal of minimizing the incidence of cervical cancer. Our commitment to women's health, along with our industry leading quality-assurance practices, makes us imminently qualified to deliver the superior testing services that Irish women deserve."

Quest Diagnostics' relationship with the medical community of Ireland began in 2006, when the Health Service Executive (HSE), the national health administrator for Ireland, engaged the services of Quest Diagnostics to help reduce a critical backlog of Pap-based cervical-cancer screening tests, also known as "Pap smears," that required screening. Since early 2007, Quest Diagnostics has performed approximately 50,000 Pap smears in connection with this continuing project, helping to improve the delivery of timely results.

Under the cytology-screening program, Quest Diag
'/>"/>